NCT06133556Not yet recruitingPhase 2
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
Source: ClinicalTrials.gov · Last updated 15 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The classical Bu / Cy scheme or MCBC scheme was used for pretreatment. The primary endpoint of the study was the 3-year recurrence-free survival rate after allogeneic hematopoietic stem cell transplantation, and the secondary endpoints were 3-year overall survival rate, recurrence rate, treatment-related mortality, and pretreatment-related toxicity.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 237 (estimated)
- First submitted
- 8 Sept 2023
- Start date
- 24 Nov 2023
- Primary completion date
- 20 Oct 2028
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Diseases
- Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT06133556
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 237
- From 24 Nov 2023 to the primary completion date, 20 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received hematopoietic stem cell transplantation.
Other illness
- Have a history of cancer and have received any treatment for this tumor in the past 3 years. But remove superficial bladder cancer, skin basal cells or squamous cell carcinoma, cervical epithelium. Intraepithelial neoplasia ( CIN ) or prostatic intraepithelial neoplasia ( PIN ).
- It is known that the serological reaction of HIV or active hepatitis C virus is positive.
- The inability to cooperate with the requirements of research, treatment and monitoring due to mental illness or other conditions.
Lab values
- Active heart disease, defined as one or more of the following :
- ) Uncontrolled or symptomatic angina history.
- ) Myocardial infarction less than 6 months away from the study.
- ) Have a history of arrhythmia requiring drug treatment or severe clinical symptoms.
- ) Uncontrolled or symptomatic congestive heart failure ( \> NYHA class 2 ).
- ) The ejection fraction is lower than the lower limit of the normal range.
Other
- MPAL.
- Pregnant patients or patients who could not take appropriate contraceptive measures during treatment.
- Researchers evaluated that is not suitable for the group.
Who the study is looking for
- Refractory / relapsed AML.
- Patients with a HLA matched related or unrelated donor (9\~10/10) or haplo-identical related donor, plan to receive HSCT.
- Age ≤ 60 years old, men and women are not limited.
- The Eastern Oncology Collaborative Group Physical Status Assessment ( ECOG-PS ) was 0-2 points.
- Informed consent must be signed before the start of the study procedure. Informed consent must be signed by the patient or his or her immediate family members who are 18 years of age or older ; informed consent was signed by the legal guardian for children and adolescent patients under 18 years old. Considering the patient 's condition, if the patient 's signature is not conducive to the treatment of the disease, the informed consent is signed by the legal guardian or the patient 's immediate family.
Age in the registry: - to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.